Michal Ayalon, Ph.D., has been appointed vice president of R&D, Kamada Ltd. Dr. Ayalon has 20 years of experience in drug discovery and drug development, including non-clinical and clinical development, manufacturing and control, regulatory, and project management. She will oversee all of Kamada’s R&D and IP activities, and report directly to Amir London, Kamada’s chief executive officer. Dr. Ayalon succeeds Liliana Bar, Ph.D. who has served as Kamada’s VP R&D since 2012 and is...